RAS MUTATION
Clinical trials for RAS MUTATION explained in plain language.
Never miss a new study
Get alerted when new RAS MUTATION trials appear
Sign up with your email to follow new studies for RAS MUTATION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a new pill outsmart RAS-Mutant cancers?
Disease control Not yet recruitingThis early-stage trial is testing an experimental oral drug called BG-85738 in people with advanced or metastatic solid tumors that have RAS mutations. The study aims to see if the drug is safe and tolerable when given alone or combined with other anti-cancer agents, and to get a…
Matched conditions: RAS MUTATION
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Smart drug targets two cancer weaknesses at once
Disease control Not yet recruitingThis trial tests a new drug called AN4035 in people with advanced solid tumors that have RAS mutations and high levels of the CEACAM5 protein. The drug is designed to seek out cancer cells carrying CEACAM5 and deliver a payload that blocks RAS, a key driver of cancer growth. The …
Matched conditions: RAS MUTATION
Phase: PHASE1 • Sponsor: Adlai Nortye Biopharma Co., Ltd. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with RAS mutations
Disease control Not yet recruitingThis study tests an experimental oral drug called GFH276 combined with either cetuximab or standard chemotherapy in people with advanced solid tumors or pancreatic ductal adenocarcinoma (PDAC) that have a RAS mutation. The goal is to see if the combination is safe, tolerable, and…
Matched conditions: RAS MUTATION
Phase: PHASE1, PHASE2 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC